The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.
Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
ResMed has had an impressive run over the past six months as its shares have beaten the S&P 500 by 11.9%. The stock now trades at $281.96, marking a 20.7% gain. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Wednesday. Discover the gap up and gap down stocks in the S&P500 index.
Each stock in this article is trading near its 52-week high.
These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.
Medical device company ResMed (NYSE:RMD) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.2% year on year to $1.35 billion. Its non-GAAP profit of $2.55 per share was 3% above analysts’ consensus estimates.
ResMed (RMD) offers a strong dividend with steady growth, backed by solid profitability and financial health, making it ideal for long-term income investors.
Shares of medical device company ResMed (NYSE:RMD)
jumped 3.1% in the afternoon session after the company reported strong fourth-quarter financial results that surpassed analyst estimates.
Medical device company ResMed (NYSE:RMD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 10.2% year on year to $1.35 billion. Its non-GAAP profit of $2.55 per share was 3% above analysts’ consensus estimates.
ResMed trades at $254.11 per share and has stayed right on track with the overall market, gaining 8.9% over the last six months. At the same time, the S&P 500 has returned 5.4%.
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
RESMED INC (NYSE:RMD) is a high-quality stock with strong revenue growth, exceptional ROIC, and solid cash flow, making it a standout pick for long-term investors.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
